sumatriptan/naproxen / Generic mfg. - LARVOL DELTA

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

SMART: Use of the Combination of Sumatriptan and Naproxen in the Acute Treatment of Migraine: Real World Evidence Study (clinicaltrials.gov) - P=N/A | N=300 | Not yet recruiting | Sponsor: IRCCS San Raffaele Roma

HEOR • New trial • Real-world evidence • CNS Disorders • Migraine • Pain

Treatments of Migraine with Triptans in Individuals with Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Completed | Sponsor: Mayo Clinic | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • CNS Disorders • Migraine • Pain

Sumatriptan-naproxen sodium in migraine: A review. (PubMed, Eur J Neurol) - "Multi-mechanistic therapeutic agents offer an opportunity to optimise acute medications by targeting multiple mediators involved in the pathogenesis of migraine. Sumatriptan-naproxen sodium resulted in greater initial and sustained pain freedom, compared with either sumatriptan, naproxen-sodium and/or placebo, for the treatment of single or multiple attacks of migraine across both adult and adolescent study populations."

Journal • Review • CNS Disorders • Migraine • Pain

SK chemicals launches 1st combo migraine treatment in Korea (Korea Biomedical Review) - "SK chemicals said it launched the first combination migraine treatment, Suvexx, in Korea. The drug combines two active ingredients—sumatriptan, a triptan commonly used for migraine relief, and naproxen sodium, a nonsteroidal anti-inflammatory drug (NSAID)."

Launch non-US • CNS Disorders • Migraine • Pain

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Aug 2023 ➔ Aug 2024

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Migraine • Pain

Sumatriptan-naproxen sodium fix-dose combination for acute migraine treatment, a review (PubMed, Ideggyogy Sz) - "Furthermore the combination showed beneficial effect on accompanying symptoms of migraine attack (i.e. nausea, photo- and phonophobia). Adverse events were mild or moderate in severity and rarely led to withdrawal of the drug.It can be concluded that sumatriptan (85 mg)/naproxen sodium (500 mg) fix-dose combination is effective, safe and well-tolerated in the acute treatment of migraine. ."

Clinical • Journal • Review • CNS Disorders • Migraine • Pain

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic | Trial completion date: Aug 2023 ➔ Dec 2023 | Trial primary completion date: Mar 2023 ➔ Aug 2023

Trial completion date • Trial primary completion date • Cardiovascular • CNS Disorders • Migraine • Pain

Searchlight Pharma Announces Suvexx Launch in Europe, along with Deal Expansion to all E.U. Markets (Businesswire) - "Searchlight Pharma Inc...today announced that Orion Corporation...has launched Suvexx® in select countries covered in the 2020 exclusive license and supply agreement (the 'License Agreement') between Nuvo Pharmaceuticals (Ireland) DAC ('Nuvo Ireland') and Orion, with the product launches continuing into 2024....Nuvo Ireland and Orion have also entered into an amendment to the original License Agreement for the exclusive right to package, distribute, market and sell Suvexx in all remaining E.U. countries outside of the original License Agreement Territory. Orion anticipates filing the marketing authorization application immediately and expects to commercially launch Suvexx in Austria, Belgium, the Czech Republic, France, Germany, Greece, Ireland, Italy, the Netherlands, Portugal, Slovakia, Spain, Switzerland and the U.K. during 2024, subject to receipt of marketing authorization and pricing approval."

Launch Europe • Licensing / partnership • CNS Disorders • Migraine • Pain

Drugs for migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review. (PubMed, Indian Pediatr) - "We found that rizatriptan (good tolerability profile with a dose of 5 mg) and sumatriptan (oral administration) had higher efficiency as compared to other triptans. Regardless of type or dose, all triptans are generally well tolerated by patients, but a few adverse effects such as light-headedness (sumatriptan), nasopharyngitis, and, muscular spasms (sumatriptan/ naproxen), somnolence, and dry mouth (rizatriptan), and dizziness (zolmitriptan group) were reported with the triptans."

Journal • Review • CNS Disorders • Infectious Disease • Migraine • Pain • Pediatrics • Xerostomia

Treatments of Migraine With Triptans in Individuals With Elevated Cardiovascular Risk and in Pregnant Women (clinicaltrials.gov) - P=N/A | N=68419 | Active, not recruiting | Sponsor: Mayo Clinic

New trial • Cardiovascular • CNS Disorders • Migraine • Pain

Miravo Healthcare Enters into Definitive Agreement to be Acquired by Searchlight Pharma Inc. (Businesswire) - "Nuvo Pharmaceuticals Inc. d/b/a Miravo Healthcare...and Searchlight Pharma Inc., a private Canadian-based specialty healthcare company...are pleased to announce that they have entered into a definitive agreement (the 'Arrangement Agreement') pursuant to which the Purchaser has agreed to acquire all of the issued and outstanding common shares of the Company (the 'Company Shares') in exchange for cash consideration of $1.35 per Company Share, representing a 79.8% premium to the 90-day volume-weighted average trading price of the Company Shares on the Toronto Stock Exchange for the period ended December 22, 2022....'Not only does an all-cash transaction provide immediate and certain value to shareholders, it also allows important healthcare products like...Cambia® and Suvexx® to remain available to healthcare providers and patients through the enhanced scale of the Searchlight business.'"

M&A • CNS Disorders • Migraine • Pain

Insights into melatonin-induced photosynthetic electron transport under low-temperature stress in cucumber. (PubMed, Front Plant Sci) - "The loss of the slow phase of MT 200 and MT 400-treated plants in the MR kinetics was due to the complete prevention of electron movement from PSII to re-reduce the PC and P700 . These results suggest that appropriate MT concentration (100 μmol · L) can improve the photosynthetic performance of PS II and electron transport from primary quinone electron acceptor (Q) to secondary quinone electron acceptor (Q), promote the balance of energy distribution, strengthen the connectivity of PSI and PSII, improve the electron flow of PSII via Q to PC and P from reaching PSI by regulating multiple sites of electron transport chain in photosynthesis, and increase the pool size and reduction rates of PSI in low temperature-stressed cucumber plants, All these modifications by MT 100 treatment promoted the photosynthetic electron transfer smoothly, and further restored the cucumber plant growth under low temperature stress. Therefore, we conclude that spraying MT at an..."

Journal

Miravo Healthcare Announces Third Quarter 2022 Results (Businesswire) - "Revenue related to the...Cambia® and Suvexx® was $10.7 million, an increase of 32% compared to revenue of $8.1 million for the three months ended September 30, 2021. Total Canadian prescriptions of...Cambia and Suvexx increased by 27%, 7% and 86%, respectively compared to the three months ended September 30, 2021."

Commercial • CNS Disorders • Migraine • Pain

Electrochemical Sensor Based on Ni-Co Layered Double Hydroxide Hollow Nanostructures for Ultrasensitive Detection of Sumatriptan and Naproxen. (PubMed, Biosensors (Basel)) - "Simultaneous analysis of sumatriptan with naproxen showed well-separated peaks leading to a quick and selective analysis of sumatriptan. Furthermore, the practical applicability of the prepared Ni-CO LDH/SPE sensor was examined in pharmaceutical and biological samples with satisfactory recovery results."

Journal

Systemic administration of monosodium glutamate induces sexually dimorphic headache- and nausea-like behaviours in rats. (PubMed, Pain) - "The behavior of male and female Sprague Dawley rats was video recorded before and after intraperitoneal (i.p.) injections of either MSG (1-1000 mg/kg), nitroglycerin (GTN, 10 mg/kg) or normal saline...Co-administration of sumatriptan or naproxen with MSG (1000 mg/kg), significantly attenuated MSG-induced nocifensive and headache-like behaviors. Our data suggests that systemic administration of MSG to rats induces behavioral correlates of headache and nausea. This model may offer another avenue for research on the mechanism and treatment of primary headache disorders such as migraine."

Journal • Preclinical • Anesthesia • CNS Disorders • Immunology • Migraine • Pain

Spontaneous, Voluntary, and Affective Behaviours in Rat Models of Pathological Pain. (PubMed, Front Pain Res (Lausanne)) - "Pharmacological treatment of the distinct pain conditions was performed with pathology-specific and clinically efficacious analgesics as gabapentin, sumatriptan, naproxen, and codeine. Based on all behavioural test performed, we screened for tests that can discriminate experimental groups on the basis of reflexive as well as non-sensory, affective parameters. Together, we propose a set of non-evoked behaviours with a comparable predictive power to mechanical threshold testing for each pain model."

Journal • Preclinical • CNS Disorders • Depression • Immunology • Mood Disorders • Pain • Psychiatry

Voltammetric detection of sumatriptan in the presence of naproxen using FeO@ZIF-8 nanoparticles modified screen printed graphite electrode. (PubMed, Sci Rep) - "The modified electrode showed two separate oxidative peaks at 620 mV for sumatriptan and at 830 mV for naproxen with a peak potential separation of 210 mV which was large enough to detect the two drugs simultaneously besides being stable in the long-run with considerable reproducibility. Real sample analyses were carried out to identify the function of fabricated electrode in sensing applications wherein trace amounts of sumatriptan and naproxen could be identified in these samples."

Journal

Nuvo Pharmaceuticals' (MRVFF) CEO Jesse Ledger on Q3 2021 Results - Earnings Call Transcript (SeekingAlpha) - "Our three key promoted products, Blexten, Cambia and Suvexx continue to demonstrate year-over-year prescription growth, and generated $8.1 million in revenue for Q3....Finland, the Finnish regulatory approval decision is expected in Q2 or Q3 of 2022 with the commercial launch anticipated in Q1 2023"

Commercial • European regulatory • Launch Europe • CNS Disorders • Migraine • Pain

Miravo HealthcareTM Ireland Enters into Suvexx License and Supply Agreement with SK Chemicals Co., Ltd. for South Korea (PRNewswire) - "Nuvo Pharmaceuticals...announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC trading as Miravo Healthcare ('Miravo Ireland'), has entered into an exclusive license and supply agreement (the 'License Agreement') with SK Chemicals Co., Ltd. ('SK Chemicals') for the exclusive right to commercialize Suvexx in the Republic of South Korea (the 'Territory')...The commercial launch of Suvexx in the Territory is anticipated to commence in 2023...Upon regulatory approval, Suvexx is anticipated to be entitled to 6 years of marketing exclusivity in the Territory. The South Korean prescription acute migraine treatment market was valued at over US$20 million in 2020 based on IQVIA domestic data."

Launch non-US • Licensing / partnership • CNS Disorders • Migraine • Pain

Study of Sumatriptan Naproxen Sodium Succinate Tablets for the Treatment of Acute Migraine Attacks (clinicaltrials.gov) - P3; N=240; Recruiting; Sponsor: Peking University Third Hospital

Clinical • New P3 trial • CNS Disorders • Migraine • Pain

[VIRTUAL] Simultaneous comparisons of 22 acute migraine medications: A big data analysis of 10 million patient self-reported treatment records from a migraine smartphone application (AHS 2021) - " The medication candidate with the highest self-reported effectiveness outcome measure is the commercially available combination of sumatriptan/naproxen (OR 2.68), followed by sumatriptan (OR 2.10), and eletriptan (OR 2.05), and other triptans. The odds ratios for barbiturate, acetaminophen, NSAID, and opioids ranges from 1.58 to 1.03, except for meloxicam (OR 0.80)... To our knowledge, this is the first study to leverage real-world patient experience gathered via a migraine tracking app that is large enough to support simultaneous direct head-to-head comparisons of different classes of acute migraine medications. The finding that triptans, compared to barbiturate, acetaminophen, NSAID, and opioids, are the most efficacious medications is generally consistent with treatment guidelines that are based on results from randomized controlled trials and clinical experience. By leveraging real-world patient reported outcome, this platform offers dynamic, generalizable real-time..."

Clinical • CNS Disorders • Migraine • Pain

Drugs for Migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Miravo Healthcare Ireland Enters into Suvexx License and Supply Agreement with Orion Corporation for Select EU Markets (PRNewswire) - "Nuvo Pharmaceuticals Inc....d/b/a Miravo Healthcare (Miravo or the Company)...today announced that its wholly owned subsidiary, Nuvo Pharmaceuticals (Ireland) DAC...has entered into an exclusive license and supply agreement (the License Agreement) with Orion Corporation (Orion) for the exclusive right to package, distribute, market and sell Suvexx in Finland, Sweden, Denmark, Norway, Poland, Hungary, Latvia, Lithuania and Estonia (the Territory)....The commercial launch of Suvexx in the Territory is anticipated to commence in 2022, subject to regulatory approval....Miravo Ireland will receive up to EUR 1.7 million in upfront consideration, regulatory and sales-based milestone payments, as well as royalties on net sales of Suvexx in the Territory and revenue pursuant to the supply of product."

Launch Europe • Licensing / partnership • CNS Disorders • Migraine • Pain